retatrutide phase 2 nejm 2023 obesity trial results in adults with over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide Phase 2 NEJM Trial:

Patients showed elevated insulin levels and a decrease in systolic blood pressure

| Todos los derechos reservados | COFEPRIS: 153300201A2530 233300201B1337 Consulte a su mdico *Precio sugerido, el precio puede cambiar de acuerdo al estado o regin donde se encuentre

This extends its effective half-life to approximately 2030 hours and dramatically amplifies its biological activity compared to the native hormone

10 As shown in FIGURE 3 , exenatide normalizes blood glucose levels by reducing fasting and postprandial glucose concentrations through a variety of mechanisms, including enhanced glucose-dependent insulin secretion, regulation of glucagon secretion, delayed gastric emptying, and decreased food intake due to centrally mediated effects on satiety

And when one medication doesnt cover it all, a combination might

doi: 10.2337/dc20-2151 53 FDA News release